Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 8/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967331 | 0.86 | KMT2A (0.66) | KMT2ACYP2A13LMNAACHEKDM4E | |
| SCHEMBL6791318 | 0.85 | HTR7 (0.59) | HTR7KMT2ACYP2A13LMNAACHE | |
| SCHEMBL1111683 | 0.80 | HTR7 (0.64) | HTR7MPO | |
| SCHEMBL3962168 | 0.80 | KMT2A (0.49) | HTR7KMT2ACYP2A13LMNAACHE | |
| SCHEMBL1111758 | 0.79 | HTR7 (0.40) | HTR7KMT2ACYP2A13LMNAACHE | |
| SCHEMBL1111917 | 0.78 | ACHE (0.49) | HTR7KMT2ALMNAACHEKDM4E | |
| SCHEMBL11371772 | 0.78 | ACHE (0.56) | HTR7KMT2ACYP2A13LMNAACHE | |
| SCHEMBL1111800 | 0.77 | HTR7 (0.60) | HTR7 | |
| SCHEMBL1111726 | 0.76 | HTR7 (0.48) | HTR7LMNAKDM4EALDH1A1NPC1 | |
| SCHEMBL1111682 | 0.75 | HTR7 (0.56) | HTR7KMT2ALMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
| EP-2279174-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Genentech, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009143246-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAX, API5, BCL2 | HTR7 2134/4885KMT2A 4447/4885CYP2A13 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.